Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIFRA: Cetuximab + FOLFIRI in FcγRIIIa V/V mCRC
NCT03874026Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2019
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in colorectal cancer (CRC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 1 year. Started Sep 2019; status: recruiting.
02
Drugs
KL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03874026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03874026.